Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh

Hdl Handle:
http://hdl.handle.net/10144/550531
Title:
Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh
Authors:
Lucero, Emiliano; Collin, Simon M; Gomes, Sujit; Akter, Fatima; Asad, Asaduzzam; Kumar Das, Asish; Ritmeijer, Koert
Journal:
PLoS Neglected Tropical Diseases
Abstract:
Bangladesh is one of the endemic countries for Visceral Leishmaniasis (VL). Médecins Sans Frontières (MSF) ran a VL treatment clinic in the most endemic district (Fulbaria) between 2010 and 2013 using a semi-ambulatory regimen for primary VL of 15mg/kg Liposomal Amphotericin-B (AmBisome) in three equal doses of 5mg/kg. The main objective of this study was to analyze the effectiveness and safety of this regimen after a 12 month follow-up period by retrospective analysis of routinely collected program data. A secondary objective was to explore risk factors for relapse.
Publisher:
Public Library of Science
Issue Date:
2-Apr-2015
URI:
http://hdl.handle.net/10144/550531
DOI:
10.1371/journal.pntd.0003699
PubMed ID:
25837313
Language:
en
ISSN:
1935-2735
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorLucero, Emilianoen_GB
dc.contributor.authorCollin, Simon Men_GB
dc.contributor.authorGomes, Sujiten_GB
dc.contributor.authorAkter, Fatimaen_GB
dc.contributor.authorAsad, Asaduzzamen_GB
dc.contributor.authorKumar Das, Asishen_GB
dc.contributor.authorRitmeijer, Koerten_GB
dc.date.accessioned2015-04-23T20:39:53Z-
dc.date.available2015-04-23T20:39:53Z-
dc.date.issued2015-04-02-
dc.identifier.citationEffectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh. 2015, 9 (4):e0003699 PLoS Negl Trop Disen_GB
dc.identifier.issn1935-2735-
dc.identifier.pmid25837313-
dc.identifier.doi10.1371/journal.pntd.0003699-
dc.identifier.urihttp://hdl.handle.net/10144/550531-
dc.description.abstractBangladesh is one of the endemic countries for Visceral Leishmaniasis (VL). Médecins Sans Frontières (MSF) ran a VL treatment clinic in the most endemic district (Fulbaria) between 2010 and 2013 using a semi-ambulatory regimen for primary VL of 15mg/kg Liposomal Amphotericin-B (AmBisome) in three equal doses of 5mg/kg. The main objective of this study was to analyze the effectiveness and safety of this regimen after a 12 month follow-up period by retrospective analysis of routinely collected program data. A secondary objective was to explore risk factors for relapse.en_GB
dc.language.isoenen
dc.publisherPublic Library of Scienceen_GB
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen_GB
dc.titleEffectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladeshen
dc.identifier.journalPLoS Neglected Tropical Diseasesen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.